AGP Executive Report
Last update: 12 hours agoCancer R&D Update: Agenus says Phase 1b data for botensilimab plus balstilimab in treatment-refractory hepatocellular carcinoma has been published in Liver Cancer, reporting an 18-patient efficacy set with a 17% objective response rate and 50% clinical benefit at 18 weeks. Breast Cancer Access: Enhertu (fam-trastuzumab deruxtecan) won two new U.S. approvals for HER2-positive early breast cancer—neoadjuvant (with THP) and adjuvant (for residual invasive disease). Diabetes Drug Watch: Dr. Reddy’s announced it launched generic semaglutide injection in Canada after Health Canada’s NOC, positioning it as among the first in a G7 market. System Pressure (Ontario): Nurses warn Ontario’s health-care system is at a breaking point as wait-time strain and workforce cuts intensify. Public Health—Opioids: Canadian health and public safety leaders reiterate supervised consumption sites still matter, but must evolve alongside housing and broader safety strategies.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
